Preclinical studies using Ewing sarcoma cell lines and Ewing xenografts have demonstrated tumor sensitivity to compounds that prevent DNA damage repair such as PARP1 inhibitors (PARPi; refs. 6–8). Here, PARP1 is linked to Ewing sarcoma.